::: {.question-block}

<form onsubmit="event.preventDefault(); checkAnswer('module4_mcq_q93')" data-correct-answer="C">
  <strong style="display: block;">
  Suppose a biotechnology startup has no debt and negative earnings, but high expected future growth. If an analyst applies CAPM with a high beta estimated from volatile peers, what risk of misinterpretation exists?
  </strong>

  <label><input type="radio" name="module4_mcq_q93" value="A"> A. CAPM cannot be applied to firms without positive earnings.</label><br>
  <label><input type="radio" name="module4_mcq_q93" value="B"> B. The estimated beta will always overstate the true cost of equity for startups.</label><br>
  <label><input type="radio" name="module4_mcq_q93" value="C"> C. A high beta from peers may reflect short-term volatility rather than the true systematic risk of the startup’s cash flows.</label><br>
  <label><input type="radio" name="module4_mcq_q93" value="D"> D. CAPM automatically accounts for future growth opportunities, so beta is irrelevant.</label><br>
  <label><input type="radio" name="module4_mcq_q93" value="E"> E. The risk-free rate dominates the calculation in all startup valuations.</label><br>
</form>

<div id="feedback-module4_mcq_q93" class="feedback" data-status="" style="display:none;">
✅ Correct: C. Using peer betas can overstate risk if they capture volatility unrelated to the startup’s long-term systematic exposure.
</div>

:::
